Director or Officer Departures, Elections, Appointments, and Compensation Arrangements

Business Context and Reporting Period

This Form 8-K is a current report filed by Hemab Therapeutics Holdings, Inc. (COAG) on May 11, 2026, covering events occurring on May 8, 2026. The company is incorporated in Delaware and operates as an emerging growth company.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes rather than financial performance.

Material Changes

On May 8, 2026, Laura Tadvalkar, Ph.D., resigned as a member of the Company's Board of Directors, effective immediately. The Company stated that the resignation was not related to any disagreement with the Company regarding its operations, policies, or practices.

Guidance, Outlook, and Risks

The filing contains no management commentary, financial guidance, or outlook. No specific risks or contingencies were disclosed in this report other than the standard disclosure regarding the director's departure.

Investor Verification Checklist

  • Verify the current composition of the Board of Directors following Dr. Tadvalkar's resignation.
  • Confirm whether the Board intends to appoint a replacement director and the timeline for such appointment.
  • Review recent press releases or other filings to ensure no undisclosed disagreements or operational issues preceded the resignation.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.